HemCon Medical Technologies, a developer of lyophilized human plasma, has named Barry Starkman as the new chief executive officer (CEO).

Previously, Starkman served at Promega as operational vice president, where he was responsible for providing manufacturing, planning and logistics services for the $300m organization.

Starkman also served as general manager at Genentech, where he has overseen the design, construction, start-up and operation of $450m formulation, packaging and distribution facility in Portland, Oregon, US.

As new CEO, Starkman will focus on the execution and delivery of the lyophilized plasma program (LyP program) through Phase 2 clinical trials as well as expand facility to allow the company to enter Phase 3 clinical trials for the LyP program.

Starkman will also review the medical device division to determine the optimal means by which the business can be developed and contribute towards the company’s overall financial performance.

HemCon Medical Technologies chairman and co-founder Bill Wiesmann said, "His leadership and expertise will prove valuable in realizing the full potential of our LyP program, and in developing the optimal strategy for the Medical Device division."